Excitotoxic neuronal death and the pathogenesis of Huntington's disease.
暂无分享,去创建一个
[1] M. Hayden,et al. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.
[2] J. Epplen,et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner , 2007, Human Genetics.
[3] L. Massieu,et al. Exacerbation of excitotoxic neuronal death induced during mitochondrial inhibition in vivo: Relation to energy imbalance or ATP depletion? , 2007, Neuroscience.
[4] L. Raymond,et al. Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[5] L. Raymond,et al. N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.
[6] Carlos Cepeda,et al. The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.
[7] A. Camacho,et al. Sustained metabolic inhibition induces an increase in the content and phosphorylation of the NR2B subunit of N-methyl-d-aspartate receptors and a decrease in glutamate transport in the rat hippocampus in vivo , 2007, Neuroscience.
[8] T. Videen,et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum , 2007, Proceedings of the National Academy of Sciences.
[9] J. Ryu,et al. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington’s disease , 2006, Neuroscience.
[10] L. Massieu,et al. d-β-Hydroxybutyrate Prevents Glutamate-Mediated Lipoperoxidation and Neuronal Damage Elicited during Glycolysis Inhibition In Vivo , 2006, Neurochemical Research.
[11] M. Beal,et al. PGC-1α, a New Therapeutic Target in Huntington's Disease? , 2006, Cell.
[12] S. Luquet,et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.
[13] Jiandie D. Lin,et al. Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.
[14] Dimitri Krainc,et al. Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.
[15] A. Spada,et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport , 2006, Nature Neuroscience.
[16] M. Levine,et al. Changes in Expression of N-Methyl-D-Aspartate Receptor Subunits Occur Early in the R6/2 Mouse Model of Huntington’s Disease , 2006, Developmental Neuroscience.
[17] R. Ferrante,et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. , 2006, Biochimica et biophysica acta.
[18] R. Schwarcz,et al. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease , 2006, Experimental Neurology.
[19] Ji-Yeon Shin,et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.
[20] Elena Cattaneo,et al. Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.
[21] C. Cepeda,et al. Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.
[22] G. Johnson,et al. Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin* , 2005, Journal of Biological Chemistry.
[23] Hervé Chneiweiss,et al. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. , 2005, Human molecular genetics.
[24] R. Llinás,et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Epplen,et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease , 2005, Neurogenetics.
[26] S. Augood,et al. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.
[27] F. Pedata,et al. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow , 2004, Neurobiology of Disease.
[28] I. Bezprozvanny,et al. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5‐trisphosphate‐induced Ca2+ release in primary culture of striatal medium spiny neurons , 2004, The European journal of neuroscience.
[29] J. Schiefer,et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.
[30] M. MacDonald,et al. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.
[31] M. Beal,et al. The Energetics of Huntington's Disease , 2004, Neurochemical Research.
[32] L. Raymond,et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease , 2004, Molecular and Cellular Neuroscience.
[33] R. Scarpulla,et al. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. , 2004, Genes & development.
[34] L. Raymond,et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease , 2003, Neurobiology of Aging.
[35] Ruth Luthi-Carter,et al. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation , 2003, Neurobiology of Disease.
[36] S. Swinnen,et al. Creatine supplementation in Huntington’s disease , 2003, Neurology.
[37] M. MacDonald,et al. Neocortical neurons cultured from mice with expanded cag repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults , 2003, Neuroscience.
[38] C. Parsons,et al. Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.
[39] He Li,et al. Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease , 2003, The Journal of Neuroscience.
[40] M. MacDonald,et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. , 2003, Human molecular genetics.
[41] U. Bonuccelli,et al. Amantadine in Huntington's disease: open-label video-blinded study , 2002, Neurological Sciences.
[42] K. Lindenberg,et al. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.
[43] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[44] C. Arias,et al. β-Amyloid Neurotoxicity Is Exacerbated during Glycolysis Inhibition and Mitochondrial Impairment in the Rat Hippocampus in Vivo and in Isolated Nerve Terminals: Implications for Alzheimer's Disease , 2002, Experimental Neurology.
[45] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[46] Ole A. Andreassen,et al. Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.
[47] H. Robertson,et al. Immediate‐early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice , 2002, Journal of neuroscience research.
[48] C. Cepeda,et al. NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.
[49] A. Mahal,et al. Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.
[50] P. Reddy,et al. Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.
[51] O. Andreassen,et al. Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.
[52] Mark Farrant,et al. NMDA receptor subunits: diversity, development and disease , 2001, Current Opinion in Neurobiology.
[53] L. Massieu,et al. Strategies for neuroprotection against L‐trans‐2,4‐pyrrolidine dicarboxylate‐induced neuronal damage during energy impairment in vitro , 2001, Journal of neuroscience research.
[54] J. Penney,et al. The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.
[55] Michael R. Hayden,et al. Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.
[56] O. Hansson,et al. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice , 2001, The European journal of neuroscience.
[57] G. Battaglia,et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective , 2000, Neuropharmacology.
[58] N. Gomez-roman,et al. In Vivo Potentiation of Glutamate-Mediated Neuronal Damage after Chronic Administration of the Glycolysis Inhibitor Iodoacetate , 2000, Experimental Neurology.
[59] A. Morton,et al. Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity , 2000, Brain Research Bulletin.
[60] J. Brotchie,et al. NMDA receptors in the basal ganglia , 2000, Journal of anatomy.
[61] R. Schwarcz,et al. Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model , 2000, Neuroscience Letters.
[62] M. MacDonald,et al. Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease , 1999, Neurology.
[63] L. Raymond,et al. Influence of lamotrigine on progression of early Huntington disease , 1999, Neurology.
[64] O. Hansson,et al. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[65] L. Raymond,et al. Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.
[66] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[67] S. Tabrizi,et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.
[68] L. Massieu,et al. Transient Inhibition of Glutamate Uptake In Vivo Induces Neurodegeneration when Energy Metabolism Is Impaired , 1999, Journal of neurochemistry.
[69] Í. Lopes-Cendes,et al. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. , 1998, Archives of neurology.
[70] W. Strittmatter,et al. Glyceraldehyde 3-Phosphate Dehydrogenase Abnormality in Metabolically Stressed Huntington Disease Fibroblasts , 1998, Developmental Neuroscience.
[71] C. Garner,et al. SAP90 Binds and Clusters Kainate Receptors Causing Incomplete Desensitization , 1998, Neuron.
[72] S. W. Davies,et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[73] B R Rosen,et al. 1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.
[74] R. Gross,et al. 3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms , 1998, Neuroscience.
[75] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[76] N L Foster,et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease , 1997, Neurology.
[77] M. Beal,et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.
[78] G Norbury,et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[79] A Weindl,et al. Changes of NMDA Receptor Subunit (NR1, NR2B) and Glutamate Transporter (GLT1) mRNA Expression in Huntington's Disease—An In Situ Hybridization Study , 1997, Journal of neuropathology and experimental neurology.
[80] J Deas,et al. Ion homeostasis in brain cells: differences in intracellular ion responses to energy limitation between cultured neurons and glial cells , 1997, Neuroscience.
[81] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[82] M. Mcdermott,et al. A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[83] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[84] A. Roses,et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH , 1996, Nature Medicine.
[85] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[86] J. Bockaert,et al. NMDA-dependent superoxide production and neurotoxicity , 1993, Nature.
[87] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[88] Bert Sakmann,et al. Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes , 1992, Science.
[89] H. Herzog,et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.
[90] J. Penney,et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.
[91] J. Penney,et al. NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.
[92] A. Novelli,et al. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.
[93] R. Schwarcz,et al. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[94] G. Reynolds,et al. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease , 1986, Neuroscience Letters.
[95] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[96] G. Graveland,et al. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. , 1985, Science.
[97] G. Reynolds,et al. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases , 1985, Journal of the Neurological Sciences.
[98] R. Schwarcz,et al. II: Excitotoxic models for neurodegenerative disorders , 1984 .
[99] A. Young,et al. A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.
[100] C. Markham,et al. Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.
[101] H. Goebel,et al. Juvenile Huntington chorea , 1978, Neurology.
[102] J. Coyle,et al. Neurochemical sequelae of kainate injections in corpus striatum and substantia nigra of the rat. , 1977, Life sciences.
[103] P. Mcgeer,et al. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.
[104] S. Dunnett,et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.
[105] M. Gerlach,et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. , 2004, Journal of neural transmission. Supplementum.
[106] D. Choi,et al. Hypoxic-Ischemic Brain Injury and Oxidative Stress , 1999 .
[107] I. R. López,et al. Enfermedad de Huntington , 1998 .
[108] R. Durbin,et al. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat , 1994, Somatic cell and molecular genetics.
[109] Peter S. Harper,et al. Huntington's disease , 1991 .
[110] P. Molinoff,et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .